Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 1

1(25.0%)

4Total

N/A(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02047084Enrolling By Invitation

Comparison of Human Allograft to Apligraf for Venous Leg Ulcers

Role: lead

NCT04040426Not ApplicableCompleted

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

Role: collaborator

NCT03999281Completed

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

Role: lead

NCT01676272Completed

Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft

Role: lead

NCT03935386Not ApplicableUnknown

Standard Compression Therapy With/Without Application of Skin Allograft (Theraskin) for Venous Leg Ulcer Treatment

Role: lead

NCT02334384Phase 1Completed

Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess

Role: collaborator

NCT00389636Not ApplicableUnknown

TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers

Role: lead

All 7 trials loaded